Bacillus Calmette-Guerin Failure in Patients with Non-Muscle-invasive Urothelial Carcinoma of the Bladder May Be Due to the Urologist's Failure to Detect Urothelial Carcinoma of the Upper Urinary Tract and Urethra

被引:24
|
作者
Giannarini, Gianluca [1 ]
Birkhaeuser, Frederic D. [1 ]
Recker, Franz [2 ]
Thalmann, George N. [1 ]
Studer, Urs E. [1 ]
机构
[1] Univ Bern, Dept Urol, Inselspital, CH-3010 Bern, Switzerland
[2] Kantonsspital Aarau, Dept Urol, Aarau, Switzerland
关键词
Bladder neoplasms; Urothelial carcinoma; Carcinoma in situ; Bacillus Calmette-Guerin; Upper urinary tract; Cytology; Follow-up studies; RADICAL CYSTECTOMY; THERAPY; CANCER;
D O I
10.1016/j.eururo.2013.09.049
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Various reasons exist for so-called bacillus Calmette-Guerin (BCG) failure in patients with non-muscle-invasive urothelial bladder carcinoma (NMIBC). Objective: To explore whether urothelial carcinoma of the upper urinary tract (UUT) and/or prostatic urethra may be a cause for BCG failure. Design, setting, and participants: Retrospective analysis of 110 patients with high-risk NMIBC repeatedly treated with intravesical BCG, diagnosed with disease recurrence, and followed for a median time of 9.1 yr. Intervention: Two or more intravesical BCG induction courses without maintenance. Outcome measurements and statistical analysis: Primary outcome was pattern of disease recurrence (BCG failure) within the urinary tract categorised into UUT and/or urethral carcinoma (with or without intravesical recurrence), and intravesical recurrence alone. Secondary outcome was survival. Predictors of UUT and/or urethral carcinoma and the effect of pattern of disease recurrence on cancer-specific survival were assessed with multivariable Cox regression analysis adjusting for multiple clinical and tumour characteristics. Results and limitations: Of the 110 patients, 57 (52%) had UUT and/or urethral carcinoma (with or without intravesical recurrence), and 53 (48%) had intravesical recurrence alone. In patientswithUUT and/or urethral carcinoma, bladder carcinoma in situ (Tis) before the first and second BCG course was present in 42 of 57 (74%) and 47 of 57 (82%) patients, respectively. On multivariable analysis, bladder Tis before the first and/or second BCG course was the only independent predictor of UUT and/or urethral carcinoma. Of the 110 patients, 69 (63%) were alive at last follow-up visit, 18 (16%) had died due to metastatic urothelial carcinoma, and 23 (21%) had died of other causes. Pattern of disease recurrence within the urinary tractwas notan independent predictor of cancer-specific survival. Main study limitations were retrospective design and limited power for survival analysis. Conclusions: In our patients with high-risk NMIBC failing after two or more courses of intravesical BCG, UUT and/or urethral carcinoma was detected in >50% of the cases during follow-up. The vastmajority of these patientshadbladder Tisbefore the firstand/or second BCG course. In patients experiencing the so-called BCG failure, a diagnostic work-up of UUT and prostatic urethra should always be performed to exclude urothelial carcinoma before additional intravesical therapy or even a radical cystectomy is considered. (C) 2013 Published by Elsevier B.V. on behalf of European Association of Urology.
引用
收藏
页码:825 / 831
页数:7
相关论文
共 50 条
  • [1] Antegrade Perfusion With Bacillus Calmette-Guerin in Patients With Non-Muscle-Invasive Urothelial Carcinoma of the Upper Urinary Tract: Who May Benefit?
    Giannarini, Gianluca
    Kessler, Thomas M.
    Birkhaeuser, Frederic D.
    Thalmann, George N.
    Studer, Urs E.
    EUROPEAN UROLOGY, 2011, 60 (05) : 955 - 960
  • [2] The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder
    Boorjian, Stephen A.
    Zhu, Fang
    Herr, Harry W.
    BJU INTERNATIONAL, 2010, 106 (03) : 357 - 361
  • [3] Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guerin after radical nephroureterectomy for upper urinary tract urothelial carcinoma
    Miyake, Makito
    Tatsumi, Yoshihiro
    Matsumoto, Hiroaki
    Nagao, Kazuhiro
    Matsuyama, Hideyasu
    Inamoto, Teruo
    Azuma, Haruhito
    Yasumoto, Hiroaki
    Shiina, Hiroaki
    Fujimoto, Kiyohide
    BJU INTERNATIONAL, 2018, 121 (05) : 764 - 773
  • [4] Treatment Options Available for Bacillus Calmette-Guerin Failure in Non-muscle-invasive Bladder Cancer
    Yates, David R.
    Brausi, Maurizio A.
    Catto, James W. F.
    Dalbagni, Guido
    Roupret, Morgan
    Shariat, Shahrokh F.
    Sylvester, Richard J.
    Witjes, J. Alfred
    Zlotta, Alexandre R.
    Palou-Redorta, Juan
    EUROPEAN UROLOGY, 2012, 62 (06) : 1088 - 1096
  • [5] Prognostic significance of Bacillus Calmette-Guerin failure classification in non-muscle-invasive bladder cancer
    Shirakawa, Hiroshi
    Kikuchi, Eiji
    Tanaka, Nobuyuki
    Matsumoto, Kazuhiro
    Miyajima, Akira
    Nakamura, So
    Oya, Mototsugu
    BJU INTERNATIONAL, 2012, 110 (6B) : E216 - E221
  • [6] Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin
    Dinney, Colin P. N.
    Greenberg, Richard E.
    Steinberg, Gary D.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (08) : 1635 - 1642
  • [7] Bacillus Calmette-Guerin intravesical instillation therapy-induced urothelial necrosis of the bladder and upper urinary tract
    Kondo, Tsubasa
    Tsurusaki, Toshifumi
    Asai, Akihiro
    Abe, Kuniko
    UROLOGY CASE REPORTS, 2022, 44
  • [8] Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma
    Milojevic, Bogomir
    Djokic, Milan
    Sipetic-Grujicic, Sandra
    Milojevic, Isidora Grozdic
    Vuksanovic, Aleksandar
    Nikic, Predrag
    Vukovic, Ivan
    Djordjevic, Dejan
    Bumbasirevic, Uros
    Tulic, Cane
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (08) : 1615 - 1620
  • [9] INTRAVESICAL BACILLUS CALMETTE-GUERIN FOR NONMUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER - PATTERNS OF USE, AND IMPACT ON OUTCOMES
    Azer, S.
    Ranasinghe, W.
    Webb, C.
    Lioufas, P. A.
    Cetti, R.
    Frydenberg, M.
    Bolton, D.
    Appu, S.
    Sengupta, S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 40 - 40
  • [10] Predictive biomarkers of response to bacillus Calmette-Guerin immunotherapy and bacillus Calmette-Guerin failure for non-muscle invasive bladder cancer
    Wang, Ziting
    So, Wei Zheng
    Loh, Kep Yong
    Lim, Yew Koon
    Mahendran, Ratha
    Wu, Qing Hui
    Chiong, Edmund
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (08) : 807 - 815